Brief: Rafael Pharmaceuticals Announces Positive Preplanned Interim Futility Analysis Of Pivotal Phase 3 Trial Of CPI-613

Rafael Holdings

01/07/2021 14:20

July 1 (Reuters) - Rafael Holdings Inc  RFL.N :
    * RAFAEL PHARMACEUTICALS ANNOUNCES POSITIVE PREPLANNED
INTERIM
FUTILITY ANALYSIS OF PIVOTAL PHASE 3 TRIAL (ARMADA 2000) OF
CPI-613® (DEVIMISTAT) FOR RELAPSED OR REFRACTORY ACUTE MYELOID
LEUKEMIA (AML)
    * RAFAEL PHARMACEUTICALS - IDMC MET ON FRIDAY, JUN. 25 AND
BASED
ON 142 WITHIN INTENTION TO TREAT POPULATION, TRIAL WAS
DETERMINED TO BE NON-FUTILE
    * RAFAEL PHARMACEUTICALS - IDMC RECOMMENDED TO CONTINUE
TRIAL AS
IS

Source text for Eikon:  ID:nGNX9D9CY1 
Further company coverage:  RFL.N 

 ((Reuters.Briefs@thomsonreuters.com;))